Literature DB >> 2897959

Beta-adrenoceptor antagonists in neuropsychiatry: an update.

M Lader1.   

Abstract

Although beta-adrenoceptor antagonists such as propranolol have been used in neuropsychiatry for more than 20 years, their indications, extent of efficacy, and place in therapy remain unclear. In this overview, which concentrates on the recent literature, four indications for use of the drugs are reviewed, with particular reference to efficacy, mode of action, and clinical utility. The indications are anxiety disorders, including performance anxiety; schizophrenia; aggressive behavior; and akathisia. The author concludes that beta-blockers are useful in some forms of anxiety disorder, perhaps those characterized by somatic symptoms and by performance anxiety, and that akathisia seems to be responsive to those drugs. However, the use of high doses of beta-blockers in schizophrenia remains unestablished, and insufficient data are available with respect to their use in aggressive behavior.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897959

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].

Authors:  P M Llorca; M A Wolf
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

2.  Increased task difficulty results in greater impact of noradrenergic modulation of cognitive flexibility.

Authors:  Heather L Campbell; Madalina E Tivarus; Ashleigh Hillier; David Q Beversdorf
Journal:  Pharmacol Biochem Behav       Date:  2007-08-19       Impact factor: 3.533

Review 3.  New drugs. Hypnotics and anxiolytics.

Authors:  B R Ballinger
Journal:  BMJ       Date:  1990-02-17

4.  Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling.

Authors:  M J Skelly; A E Chappell; E Carter; J L Weiner
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

Review 5.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.

Authors:  Inna E Tchivileva; Pei Feng Lim; Shad B Smith; Gary D Slade; Luda Diatchenko; Samuel A McLean; William Maixner
Journal:  Pharmacogenet Genomics       Date:  2010-04       Impact factor: 2.089

7.  Differentiation in the momentary rating of somatic symptoms covaries with trait emotional awareness in patients at risk for sudden cardiac death.

Authors:  Richard D Lane; Cheryl Carmichael; Harry T Reis
Journal:  Psychosom Med       Date:  2011-01-21       Impact factor: 4.312

8.  Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder.

Authors:  Luda Diatchenko; Amy D Anderson; Gary D Slade; Roger B Fillingim; Svetlana A Shabalina; Tomas J Higgins; Swetha Sama; Inna Belfer; David Goldman; Mitchell B Max; Bruce S Weir; William Maixner
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-07-05       Impact factor: 3.568

9.  Behavioral and autonomic responses to intermittent social stress: differential protection by clonidine and metoprolol.

Authors:  W Tornatzky; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

10.  Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study.

Authors:  Rachel M Zamzow; Bradley J Ferguson; Janine P Stichter; Eric C Porges; Alexandra S Ragsdale; Morgan L Lewis; David Q Beversdorf
Journal:  Psychopharmacology (Berl)       Date:  2016-01-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.